TG Therapeutics Announces Six-Year Data for BRIUMVI in RMS

Summary

TG Therapeutics Inc. announced six-year data from the ULTIMATE I & II Phase 3 trials for BRIUMVI® in relapsing forms of multiple sclerosis, showing 89.9% of patients remained disability-free with an annualized relapse rate of 0.012. The safety profile remained consistent with no new signals.Reuters

Impact Analysis

So basically, TG Therapeutics is showcasing BRIUMVI’s long-term efficacy and safety in treating RMS, which is a big deal. The six-year data presented at the ECTRIMS meeting shows that nearly 90% of patients remained disability-free, and the relapse rate is impressively low at 0.012 annually. This is a strong validation of BRIUMVI’s potential as a leading therapy in the MS space, especially given the consistent safety profile with no new signals. The timing aligns with the ECTRIMS meeting, maximizing visibility among key stakeholders. The market might be underestimating the impact of this data on TG Therapeutics’ competitive positioning and future revenue streams. With a recent share repurchase program and bullish analyst ratings, TG Therapeutics seems poised for growth. Watch for potential upward revisions in price targets as the market digests this data.Reuters+ 2